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Abstract
Species right across the evolutionary scale from insects to mammals use peptides as part of their host-defense system to
counter microbial infection. The primary structures of a large number of these host-defense peptides have been determined.
While there is no primary structure homology, the peptides are characterized by a preponderance of cationic and
hydrophobic amino acids. The secondary structures of many of the host-defense peptides have been determined by a variety
of techniques. The acyclic peptides tend to adopt helical conformation, especially in media of low dielectric constant, whereas
peptides with more than one disulfide bridge adopt L-structures. Detailed investigations have indicated that a majority of
these host-defense peptides exert their action by permeabilizing microbial membranes. In this review, we discuss structural
and charge requirements for the interaction of endogenous antimicrobial peptides and short peptides that have been derived
from them, with membranes. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
A large number of proteins that play a crucial role
in cellular physiology are in intimate association with
lipid components of cellular membranes through in-
teractions facilitated by peptide segments composed
predominantly of apolar amino acids [1,2]. There
have been extensive e¡orts to determine the features
in peptide segments that would favor membrane as-
sociation and also the orientation of peptide seg-
ments in the bilayer as well as e¡ects of membrane-
association on bilayer structure [3^8]. Peptide anti-
biotics which are hydrophobic in nature such as gra-
micidin A [9,10] and alamethicin [11,12] have been
extensively used to delineate peptide^membrane in-
teractions. Their small size and easy availability have
made it possible to study lipid^peptide interactions in
depth by a variety of biophysical techniques. Pep-
tides like gramicidin A and alamethicin were found
to have the ability to modulate ion £ux across mem-
branes and hence became popular models for under-
standing how ion channel proteins function [9^13].
In the extensive studies that have been reported,
the emphasis was on lipid^peptide interactions rather
than their biological activities. Since the early 1980s
it has become evident that peptides are an important
constituent of the host-defense mechanism against
microbes in species right across the evolutionary
scale from insects to mammals [14^22]. The amino
acid composition of these peptides, along with the
presence of cationic amino acids, suggested that
they would have the ability to associate with mem-
brane lipids. Subsequent studies indicated that these
peptides, in spite of considerable variation in primary
structure and length, exerted their biological activ-
ities by permeabilizing bacterial membranes, unlike
therapeutically used antibiotics [23^28]. To date,
the primary structures of a large number of endoge-
nous host-defense peptides have been determined.
The genes encoding these peptides have been charac-
terized and so also their expression pro¢les [15^22].
Structure^function studies on these peptides have
provided considerable insights into how this class
of peptides, which are not structurally constrained
like gramicidin A and alamethicin, modulate mem-
brane structure and also show speci¢city with respect
to target cells [15^27]. In this review, we discuss the
structural and charge requirements for the interac-
tion of antimicrobial peptides with biological and
model membranes in relation to the biological activ-
ities that have emerged from extensive investigations
in this area. It has also been possible to generate
variants of endogenous host-defense peptides much
shorter in length than the parent peptides and de-
signer peptides engineered to have comparable or
even improved activities and speci¢city as compared
to endogenous peptides, on the basis of biophysical
principles. These short peptides appear to e¡ectively
interact with membranes and exert their activities in
a manner similar to the longer peptides. We focus
our attention here on short peptides that have been
derived from host-defense peptides and engineered in
order to obtain an insight into physico-chemical
properties required for activity. We also examine
some of the recent work on magainins, cecropins
and defensins, based on which detailed models for
their interaction with membranes have been pro-
posed, with a view to explore whether a uni¢ed mod-
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el for the mechanism of peptide antibiotics can be
proposed.
2. Primary and secondary structures of endogenous
antibacterial peptides
The primary structures of host-defense antimicro-
bial peptides have been extensively documented in
several reviews [14^24], and are also available on
web sites. Hence, we have not provided an extensive
documentation in this review. However, in Table 1,
sequences of a few antibacterial peptides from di¡er-
ent species are presented in order to highlight the
extensive di¡erences in primary sequences, position-
ing of charged residues, number of disul¢de bridges
and number of residues. It is apparent that all these
peptides would be cationic at neutral pH, existing
either as the free acid or as the amide derivatives.
The defensins and other cyclic peptides have R as
the predominant cationic residue unlike cecropins
and magainins. The number of S^S bridges also
varies between one to four. Pardaxin and melittin,
though originally identi¢ed as hemolytic peptides
Table 1
Primary structures and activities of endogenous peptides possessing antibacterial and hemolytic activitiesa
aG+, G3, Gram-positive and -negative microorganism; Am, amide. Cationic residues are in bold, anionic residues are underlined.
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[29,30], also possess antibacterial activity. An exami-
nation of the biological activity pro¢les of these pep-
tides indicates that they are highly variable and not
easy to rationalize on the basis of their length, charge
or the presence/absence of S^S bridges. Even among
peptides in a particular class like cecropins, the ac-
tivities vary. Rabbit defensins are considerably more
potent than human defensins. The minimal inhibi-
tory concentration (MIC) or potencies of the various
peptides are not compared as the assays have been
performed by di¡erent methods and on di¡erent
strains of microorganisms.
Host-defense antimicrobial peptides have been the
subject of extensive structural investigations by a va-
riety of techniques. Circular dichroism (CD) has
been widely used to study their conformations in
aqueous medium, structure-promoting solvents and
lipid vesicles. These studies indicate that the linear
peptides like cecropins [31^38], magainins (reviewed
in [27]) and other frog skin peptides [20,39] are un-
ordered in aqueous medium and adopt helical struc-
tures in structure-promoting solvents like hexa£uo-
roisopropanol and tri£uoroethanol (TFE), and in
the presence of lipid vesicles. In several peptides,
the helical structure is more pronounced in the pres-
ence of anionic lipids such as phosphatidylglycerol
(PG) and phosphatidylserine (PS). The technique of
CD, though a convenient and quick method to assess
peptide conformation [40^42], has limitations. For
example, it is not possible to determine the confor-
mation at single residue or segment level. It is also
not possible to determine accurately the extent of
helix, L-sheet and L-turn structures, if they co-exist,
although several methods to deconvolute CD spectra
have been reported [43^46]. Notwithstanding these
limitations, this technique has been extensively
used, especially to compare structures of variants
and in lipid environment. A characteristic structural
feature in the linear antimicrobial peptides is that the
helix is markedly amphiphilic in nature.
Although nuclear magnetic resonance (NMR)
methods can give information about structure at sin-
gle residue/segment level [47], it has not been em-
ployed extensively in studying the conformations of
host-defense antibacterial peptides. NMR studies
have indicated that cecropin A adopts a helix^
bend^helix conformation in the presence of aqueous
hexa£uoroisopropanol [48]. However, Cecropin P1, a
variant of cecropin A, is a continuous helix [49].
Magainin 2 also a adopts helical conformation in
TFE [50]. Solid-state NMR data based on 13C and
15N chemical shifts in selectively isotope-enriched
peptides suggest that magainin occurs in helical and
L-sheet structure in the presence of lipid vesicles
[51,52]. Since chemical shifts are a reliable index of
conformation, it is likely that a fraction of magainin
molecules do indeed exist in the L-conformation.
Several recent NMR studies on peptides approxi-
mately 20^40 residues in length indicate that short
peptides do assume multiple conformations [53^57].
Hence, it is conceivable that the linear antibacterial
peptides can indeed adopt both helix and L-confor-
mation and this may re£ect on their widely di¡ering
activities when charges and hydrophobicities are
comparable. The solution structures of rabbit defen-
sin NP-2, and NP-5 and human defensin HNP-1
have been determined by NMR [58^62]. The struc-
ture of one L-defensin, BNBD-12, has also been de-
termined by NMR [63]. It is evident that both the
defensins, in spite of di¡erent S^S connectivities,
have very similar structures, especially in the L-
strand region in a L-hairpin conformation. One im-
portant feature that has emerged from NMR studies
is that human defensins exist in solution as dimers
whereas the rabbit peptides exist as monomers.
BNBD-12 also appears to exist as a monomer. De-
tailed NMR studies on insect and plant defensins
indicate that the structure of L-sheet is conserved,
especially at the C-terminal region, irrespective of
the S^S linkage pattern. However, both insect and
plant defensins have a helical segment at the N-ter-
minal region [22,64^66]. Tachyplesin, composed of
two S^S bridges, forms a rigid anti-parallel L-struc-
ture [67]. The X-ray structure of only one host de-
fense peptide with S^S bridges, HNP-3, has been
determined and the structure reveals a L-sheet con-
formation [68].
Other methods like Fourier transform infrared
spectroscopy (FTIR), attenuated total re£ectance
Fourier transform infrared spectroscopy (ATR-
FTIR), Raman spectroscopy and oriented circular
dichroism (OCD) spectroscopy have been used to a
limited extent to investigate the conformational pro-
pensities of magainin, cecropin P1 and protegrin 1
[69^72]. FTIR studies also suggest that a fraction of
magainin molecules exist in a L-conformation. ATR-
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Table 2
E¡ect of modulating charged, polar and hydrophobic residues on the activities of the 13-residue segment of SPLN,
PKLLETFLSKWIGa
aGWHf, hydrophobic moment; GHf, average hydrophobicity; Am, amide.
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FTIR and OCD studies have also allowed the deter-
mination of the orientation of the peptides at the
membrane surface.
The conformations of cecropin A and magainin 2
are shown in Figs. 1 and 2. The structures presented
are views through the helix axes. The amphiphilic
and hydrophobic nature of the cecropin helices and
the amphiphilic nature of the magainin helix are
clearly discernible. The structures of the defensins
are shown in Fig. 3. The L-sheet structure at the C-
terminal region is conserved in all of them. A helical
segment preceding the L-sheet region is observed in
insect defensin.
3. Mechanism of antimicrobial activity
In spite of the considerable variation in primary
and secondary structures, net positive charge and
distribution of positive charges along the peptide se-
quences, the host-defense antibacterial peptides have
a common mechanism of action.
Based on the observation that when the protozoa,
Paramecium cadalum, Amoeba proteus and Euglena
gracilis were exposed to magainin 2, in pond water
or distilled water, swelling of the contractile vacuoles
occurred followed by progressive swelling of the or-
ganisms, Zaslo¡ proposed that the mechanism of
action of magainin could involve membrane pertur-
bation [73]. Zaslo¡ also suggested that the membrane
a⁄nity of the peptide could arise as a result of a
strongly amphiphilic structure that would be formed
if the peptide was helical. Based on conductance ex-
periments in planar bilayers, Duclohier et al. pro-
posed that magainin formed anion-selective channels
which were weakly voltage dependent [74]. Cruciani
et al. proposed cation speci¢city for magainin 2
channels with a speci¢city ratio of 5:1 over anions
[75]. The amphiphilic nature of cecropin, and its abil-
ity to interact with membranes and form ion-selective
Fig. 1. View of cecropin helices formed by residues 5^21 and 25^37 down the helix axis. (a,b) Position of hydrophilic and hydropho-
bic side chains of segment 5^21; (c,d) positions of hydrophilic and hydrophobic residues of segment 25^37. Structures were built using
Biopolymer module of Biosym.
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channels in planar lipid bilayers [76], suggested that
cecropins too exert their antibacterial activity by per-
meabilizing bacterial membranes. The observation of
defensin-induced leakage of K and other cellular
contents and formation of voltage-dependent ion-
permeable channels in planar bilayers [77,78] indi-
cated that defensins also act on bacterial membranes
like cecropins and magainins.
The outer membrane (OM) of Gram-negative bac-
teria has negatively charged lipopolysaccharide (LPS)
molecules lining the exterior of the surface [79]. Poly-
cationic molecules bind to the OM and alter the
physical structure of the bilayer, which renders it
permeable to normally impermeant hydrophobic
molecules [80]. The cationic nature of the antibacte-
rial peptides summarized in Table 1 indicates that
they could permeabilize the bacterial OM of Gram-
negative bacteria by a similar mechanism. Several
studies which have monitored bacterial OM perme-
abilization by cationic peptides support this mode of
entry. Binding of magainin 2 to LPS results in dis-
ordering of the fatty acyl chains resulting in struc-
tural alterations in the OM^peptidoglycan com-
plexes, as suggested by altered thermotropic
properties [81,82]. Magainins also permeabilize
LPS-containing liposomes [83]. Divalent cations,
which can bind to the anionic sites in the OM, would
be expected to inhibit the activity of antimicrobial
peptides, if destabilization of the OM is necessary
to gain access to the inner membrane (IM) or cyto-
plasmic membrane. Antimicrobial activity of many
peptides including defensins, magainins and seminal-
plasmin (SPLN) are indeed inhibited by divalent cat-
ions [15,83,84]. Permeabilization of the OM by anti-
microbial peptides has been monitored by using the
hydrophobic £uorescent dye N-1-phenyl naphthyl-
amine (NPN) [85] or assaying the accessibility of
the periplasmic enzyme L-lactamase to the normally
impermeable cephalosporin substrate PADAC [86].
These molecules are impermeable to the OM and
cross the OM barrier only on permeabilization. Us-
ing these assays, defensins, indolicidin and bactene-
cins have been shown to be capable of permeabilizing
the bacterial OM [87^92].
The IM of Gram-negative bacteria is composed of
anionic lipids like phosphatidyl glycerol (PG) and
cardiolipin which would favor the association of cat-
ionic peptides. Permeabilization of the IM has been
assessed by measuring the in£ux of a normally im-
permeable chromogenic substrate to a cytoplasmic
enzyme in presence of the antimicrobial agent, L-ga-
lactosidase, and its substrate ortho nitrophenyl ga-
lactoside (ONPG) [86^92]. The substrate ONPG is
normally taken up across the IM with the help of
lac permease and in the absence of this protein trans-
porter, no ONPG in£ux is possible. Enhanced in£ux
of ONPG in the presence of an antimicrobial agent
would re£ect permeabilization of the IM. Using an
assay where permeabilization of both the OM and
IM can be concurrently measured [86], Lehrer et al.
demonstrated that in the case of human defensin
HNP-1, OM permeabilization was closely followed
by IM permeabilization and the latter event was as-
sociated with loss of viability of cells due to cessation
of respiration [88]. IM permeabilization has also
been assayed by monitoring the £uorescence of the
membrane-potential sensitive cyanine dye diS-C3-(5)
[92]. The fact that the cytoplasmic membrane may
indeed be the target of action of antimicrobial pep-
Fig. 2. View of magainin in K-helical conformation down the
helix axis. (a) Positions of hydrophilic residues; (b) positions of
hydrophobic residues. Structures were built using Biopolymer
module of Biosym.
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tides was established in a study on insect defensin A,
which e¡ectively depolarized the cytoplasmic mem-
brane of Micrococcus luteus besides causing leakage
of cytoplasmic potassium and ATP [78]. SPLN was
also capable of e¡ectively permeabilizing the cyto-
plasmic membrane of Escherichia coli cells to
ONPG, indicating that SPLN could provide an addi-
tional pathway for ONPG in£ux by permeabilizing
the IM [84]. Cecropins have the ability to induce a
hyperosmotic stress response in E. coli [93]. The au-
thors have proposed that cecropin in the periplasmic
space makes stable contacts between the inner and
outer membranes which prevent the shrinkage of the
cytoplasmic compartment in response to hyperos-
motic water in£ux.
The morphology of Gram-negative and -positive
bacteria treated with cationic antimicrobial peptides
as examined by electron microscopy clearly indicates
that the cells are killed due to disruption of the cy-
toplasmic membrane [87,94^98]. Membrane defects
were observed even at low concentration at which
the peptides were not bactericidal. However, no le-
sions in the bacterial cell surface were discernible.
Recent reports provide additional evidence that the
initial site of interaction of cationic antibacterial pep-
tides with Gram-negative bacteria is the OM. Inves-
tigation of the mechanism by which Salmonella in-
duce resistance to cationic antibacterial peptides like
PGLa and protegrins has indicated that in resistant
strains, there is acylation of lipid A by palmitic acid
[99]. This modi¢cation is presumed to alter the OM
structure so as to prevent its permeabilization by
cationic peptides. Lipid A palmitoylation in E. coli
and Yersinia enterocolitica in response to low Mg2
growth conditions also induces resistance to cationic
antibacterial peptides. Analysis of resistance pro¢les
in Bordetella species [100] have indicated that B. per-
tussis is much more susceptible to cecropins and
magainin 2 as compared to B. bronchiseptica and
this arises due to the lack of the highly negatively
charged O-speci¢c sugar side chains on the OM.
Peptides like magainins, cecropins and defensins
exert their e¡ects on the bacterial cytoplasmic mem-
brane so rapidly that it is not easy to determine
Fig. 3. Structures of K, L and insect defensin. (a,b) Hydrophilic and hydrophobic residues of K-defensin (HNP-3); (c,d) hydrophilic
and hydrophobic residues of L-defensin BNBD-12; (e,f) insect defensin A. Structures were generated from co-ordinates obtained from
Protein Data Bank.
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whether there are other intracellular targets for these
peptides. In a recent study, it has been demonstrated
that pretreatment of Staphylococcus aureus with no-
vobiocin, an inhibitor of bacterial DNA gyrase sub-
unit B, or with 50S ribosomal subunit protein syn-
thesis inhibitors such as daltopristin, blocked killing
by defensin HNP-1 [101]. However, killing of bacte-
ria by multiple mechanisms remains to be established
unequivocally. The ¢nding that all D-analogs of ce-
cropins and magainin [102,103] also exhibit antimi-
crobial activities identical to that of their natural L-
analogs have e¡ectively ruled out the involvement of
chiral recognition.
In vivo experiments in mice suggest that the anti-
bacterial activity of neutrophil defensins involves
recruitment of macrophages, granulocytes and lym-
phocytes at the site of infection [104]. Defensins
also appear to enhance systemic IgG involving
CD4 Th-1 and Th-2 type cytokines, suggesting that
innate immunity is linked to adaptive immune system
[105].
4. Identi¢cation of active peptide segments from
antibacterial peptides
Detailed structure^function studies on cecropins
and magainins have highlighted the requirement for
helical structure in the presence of lipid vesicles and
appropriately positioned cationic residues for activity
[23,24]. Extensive studies have also delineated regions
of endogenous antibacterial and hemolytic peptides
like SPLN, dermaseptin, pardaxin and melittin that
are shorter than the parent peptides but possess anti-
bacterial and/or hemolytic properties. Hybrids of ce-
cropins and melittin have also been generated with
antibacterial activities. Hemolytic peptides like melit-
tin and pardaxin have been engineered to generate
molecules with only antibacterial activity. These
studies have revealed that short peptides composed
of 11^15 residues can indeed permeabilize mem-
branes and the mechanisms of action on bacteria
are similar to that of the longer peptides. These as-
pects are reviewed in this section.
Fig. 4. View of melittin helix down the helix axis. (a,b) Position of hydrophilic and hydrophobic residues in helical segment 1^13;
(c,d) positions of hydrophilic and hydrophobic residues formed by helical segment 15^26.
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4.1. Seminalplasmin (SPLN)
SPLN, a 47-residue protein isolated from bovine
seminal plasma (sequence indicated in Table 1), has
broad-spectrum activity against Gram-negative and
-positive bacteria as well as yeast without any hemo-
lytic activity [106^108]. The protein was observed to
inhibit ribosomal RNA synthesis in E. coli and other
target microorganisms [109,110]. SPLN also had the
ability to rapidly permeabilize the outer and cyto-
plasmic membranes of E. coli, suggesting that the
protein could exert its activity by permeabilizing bac-
terial membranes [84]. The protein was also capable
of lysing dividing mammalian cells but not resting
cells [111]. Chou^Fasman analysis for the secondary
structure of SPLN predicted two possible K-helical
regions between 8^22 and 28^39 along with two L-
turns at residues 6^9 and 41^44. The Garnier^Rob-
son method of analysis suggested K-helical segments
for residues 1^10, 13^25 and 27^35 [112]. The 28^40
segment of SPLN also corresponded to its most hy-
drophobic stretch when analyzed by the method of
Kyte and Dolittle [112]. Helical wheel projections
indicated two amphiphilic K-helical regions with
clearly demarcated hydrophobic and hydrophilic
faces. Hydrophobic moment analysis according to
the Eisenberg method assigned these helical segments
to the ‘surface seeking’ region. SPLN also is known
to bind strongly to calmodulin in a Ca2-dependent
manner and functions in vitro as an antagonist [113].
Such interactions are characteristic of cationic am-
phiphilic helical peptides. Segment 13^25 showed
considerable homology to the calmodulin-interacting
segments of other proteins/peptides [114]. NMR
studies have also indicated that SPLN forms a
more compact structure in the presence of detergent
micelles with an K-helical conformation for residues
of 21^27, 31^34 and 35 to C-terminus [115].
Synthetic peptides corresponding to the putative
K-helical segments 14^26 and 28^40, as well as the
27-residue fragment (P27) encompassing both these
segments, were synthesized and evaluated for biolog-
ical activities [116^118]. These peptides, with the
sequences SLSRYAKLANRLA (SLS), PKLLET-
Fig. 5. Model depicting permeabilization of bacterial membranes by peptides. Thick lines correspond to peptides. Binding of cationic
peptides to the bacterial cell surface, which is negatively charged, results in membrane destabilization which allows entry of peptides
to the plasma membrane. The peptides bind to the membrane surface and reorient to form pores which results in membrane permea-
bilization. The structure of the toroidal pore shown in the ¢gure has been proposed by Matsuzaki and co-workers [27] and Ludtke et
al. [201].
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FLSKWIG (SPF) and SLSRYAKLANRLANPKL-
LETFLSKWIG (P27), respectively, exhibited di¡er-
ential antimicrobial activity. SLS and SPF exhibited
activity only against E. coli with MICs of 60 Wg/ml
and 50 Wg/ml, respectively, compared to 10^20 Wg/ml
of SPLN. Unlike SPLN they were inactive on Gram-
positive microorganisms. Thus, in both spectrum as
well as potency, the shorter synthetic peptides of
SPLN were less active than the parent peptide.
P27, on the other hand, exhibited antibacterial activ-
ity against Gram-negative and -positive bacteria with
MICs comparable to those of SPLN [116]. The SLS
peptide had no hemolytic activity, whereas SPF had
considerable hemolytic activity. P27 possessed hemo-
lytic activity but it was less pronounced compared to
its antimicrobial activity. SPF and P27 could rapidly
permeabilize the plasma membrane of E. coli just like
SPLN [117,118]. While it is possible that regions oth-
er than SPF or the stretch corresponding to the P27
peptide in SPLN could be responsible for the lack of
hemolytic activity and the selective activity on divid-
ing eukaryotic cells, it is clear that the segment cor-
responding to SPF is primarily responsible for the
membrane-perturbing activity of SPLN. The interac-
tions of SPLN and SPF with model membranes have
been investigated [119]. SPLN bound more strongly
to PG vesicles as compared to PC vesicles. Localiza-
tion studies indicated that the tryptophan residue in
both the peptides was located away from the lipid
head-group region. Both the peptides could cause the
release of entrapped carboxy £uorescein (CF) from
lipid vesicles. Analysis of the CF release data indi-
cated a ¢rst-order dependence on peptide concentra-
tion, suggesting that the peptides did not aggregate.
CD studies indicated that SPF and P27 adopted hel-
ical conformation in hydrophobic environment [118].
The spectra indicated that while P27 had a helical
content comparable to SPLN, that of SPF was low-
er. Synthetic peptides corresponding to the N-termi-
nal segment (1^15 residues) of SPLN did not exhibit
either antimicrobial or hemolytic activities (unpub-
lished results). Hence, an approach based on sec-
ondary structure analysis and hydrophobicity does
appear to help in identifying short peptides possess-
ing biological activity.
4.1.1. Analogs of SPF
As the 13-residue peptide SPF corresponding to
the most hydrophobic segment of SPLN inhibited
the growth of E. coli and exhibited hemolytic activ-
ity, it appeared to be an ideal molecule for studying
the various requirements for biological activity.
Hence, several analogs of SPF were synthesized
[120^124], with an aim of understanding how the
overall charge and position of charges would modu-
late its biological activity. The primary structures of
the various analogs, nature of modi¢cations and ef-
fects on activity are summarized in Table 2. The
arrangement of charged residues in SPF, i.e.,
KXXEXXXK, appeared to be important for its ac-
tivity, as interchanging of charged residues (analogs
S1 and S2) resulted in complete loss of activity [120].
Although peptides S1 and S2 were inactive, S1 had a
helical content comparable to SPF, whereas S2 was
completely unordered. The inability of S2 to acquire
helical structure could be the reason for its inactivity.
Presence of E near the C-terminal end appeared to
destabilize the helix. In the case of S1, a possible salt
bridge between E and K at positions i and i+3, could
stabilize the helical structure. Such salt bridge forma-
tion is likely to be unfavorable for membrane inter-
action. SPFE and SPFK are analogs of SPF in which
charged residues have been replaced. SPF has 2 Ks
and 1 E and carries a net charge of +1 at pH 7.0. In
SPFE both Ks of SPF were replaced by Es and in
SPFK the single E was replaced by K [120]. SPFE
was completely devoid of both antimicrobial and he-
molytic activities. Considering that a negatively
charged peptide cannot interact with anionic biolog-
ical membranes, this result would not be surprising.
On the other hand, SPFK, with a net positive charge
of +3, exhibited ¢vefold higher antimicrobial activity
compared to its parent peptide SPF, without any
discernible change in its hemolytic activity [121].
SPFK also had a much broader spectrum of antibac-
terial activity than SPF. Enhanced antimicrobial ac-
tivity of SPFK stems primarily from the increased
net positive charge on the peptide, as this modi¢ca-
tion did not bring about signi¢cant changes in hy-
drophobicity, hydrophobic moment or conforma-
tion. These analogs highlighted the importance of
positive charge on the peptide for its antimicrobial
activity. The analog SK-1, in which both the aro-
matic amino acids of SPF, F and W, were replaced
by Ls, was completely non-hemolytic, while retaining
antimicrobial activity. This suggested that, while ar-
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omatic amino acids may play a role in the interaction
of the peptides with eukaryotic membranes, they are
not critical for antimicrobial activity [120]. The other
two analogs, SK2 and SK3, were designed to check
the importance of the hydrophobic moment for bio-
logical activity. In these two analogs the sequence of
SPFK was scrambled in such a way that in SK-2
there was an increase in hydrophobic moment and
in SK-3 the hydrophobic moment was lower. SK-2
exhibited marginally increased antimicrobial activity
without any hemolytic activity and SK-3, as ex-
pected, was devoid of both the activities. The pep-
tides that exhibited antimicrobial activity could also
permeabilize lipid vesicles composed of PE and PG.
Permeabilization was determined by monitoring the
release of entrapped CF.
4.1.2. Addition and omission analogs of SPFK
Deletion or addition of amino acids in the middle
of the sequence of amphiphilic K-helical peptides can
change the relative distribution of polar and apolar
amino acids and thereby their hydrophobic mo-
ments. Hence, the consequences of selective addition
and deletion of polar and apolar amino acid residues
were investigated [122]. Several variants of SPFK
were generated by: (i) substituting S and T residues
by Ks; (ii) deletion of S and T residues individually
and together; (iii) by adding extra Ks on the polar
face of the helix; and (iv) deleting a L along with or
without T. The analogs generated, together with
their activities, are listed in Table 2. Addition of
2 Ks or replacement of S and T with Ks leads to
an increase in positive charge and was expected to
enhance the antimicrobial activity. However, no in-
crease in activity was observed. These peptides with
increased positive charge also exhibited decreased
helical content, possibly due to electrostatic repulsion
between the positively charged lysine side chains. De-
letion of S and T individually or together did not
have much e¡ect on antimicrobial activity, as such
deletions do not result in decrease in hydrophobic
moment. On the other hand deletion of L3 alone
or along with T resulted in considerable decreases
in hydrophobic moment and average hydrophobicity
and consequently loss of biological activity.
4.1.3. Cyclic analogs of SPFK
Disul¢de bridges are known to play an important
role in the stabilization of secondary structure as well
as activity in a large number of antimicrobial pep-
tides. In order to understand the e¡ect of introducing
a disul¢de bridge in a linear antimicrobial peptide,
analogs of SPFK were synthesized with cysteine res-
idues at the N- and C-terminal ends in place of the
existing amino acids [123]. While one analog had the
acid at the C-terminus, the other analog was ami-
dated. Activities of the linear analogs in which cys-
teines were protected with Acm groups and the cy-
clized analogs after deprotection were assessed.
Replacement of the terminal residues with cysteines
resulted in a decrease of both antimicrobial and he-
molytic activities. However, amidation of the C-ter-
minal carboxyl group resulted in considerable en-
hancement in antimicrobial activity without any
hemolytic activity. Cyclization of these analogs
showed dramatic increases in their hemolytic activ-
ities. The cyclic analogs associated more strongly
with lipid vesicles than the linear peptides and were
much more e¡ective in causing lysis of erythrocytes.
4.1.4. Introduction of p-£uorophenylalanine (f) into
PKLLTKFLKSWIG
The enhanced antibacterial activity of £uoroquino-
lones appears to arise due to increased hydrophobic-
ity of the molecules resulting in more e¡ective per-
meation of bacterial membranes. Hence, the e¡ect of
introducing p-£uorophenylalanine on antibacterial
activity was examined in the 13-residue peptide
PKLLTKFLKSWIG [124]. The sequences as well
as their activities are summarized in Table 2. Intro-
duction of these amino acids enhanced the antimicro-
bial activity of the peptide. Activity was also ob-
served against Candida utilis which was not seen
with the parent peptide. Although one analog
showed hemolytic activity, the concentration for
50% hemolysis was well above the MIC. Hence, p-
£uorophenylalanine appears to be a good candidate
for incorporation into a peptide in order to obtain
selective broad-spectrum antimicrobial activity.
In summary, studies on the variants of SPF indi-
cate that addition of cationic amino acids and/or
deletion of polar amino acids such as S and T can
modulate the biological activities of short peptides
composed of V13 residues. Those predicted to be
surface-active on the basis of hydrophobic moment
and average hydrophobicity values have antibacterial
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activity. However, hemolytic activity was observed
only for SPF and SPFK. Peptides possessing hemo-
lytic and antibacterial activities were most e¡ective in
permeabilizing lipid vesicles as compared to peptides
having only antibacterial activity. Also, peptides
showing selective antibacterial activity had lower pro-
pensity for helical conformation in a hydrophobic
environment.
4.2. Pardaxin
Pardaxin is an ichthyotoxic peptide secreted by
sole ¢sh of the genus Pardachirus and displays cyto-
lytic activity. The structural and charge requirements
for membrane and cytolytic activities in the toxin,
which has the sequence GFFALIPKII10 SSP-
LFKTLLS20 AVGSALSSS30 GEQE, have been ex-
tensively investigated [30]. The peptide also exhibits
broad-spectrum antibacterial activity [95]. Modi¢ca-
tion of E residues resulting in increase of positive
charge increased antibacterial potency and enhanced
hemolytic activity. Although deletion of the C-termi-
nal 10 residues resulted in a dramatic decrease in
antibacterial potency, addition of NH(CH2)2-NH2
at the C-terminal of the shortened peptide restored
antibacterial activity even when the K residues were
deleted. Peptides where the N-terminal 10 residues or
the C terminal 20 residues were deleted were inactive
even when NH^(CH2)NH2 was present at the C ter-
minus [95]. Substitution of P7 by A in pardaxin re-
sulted in enhanced hemolytic activity but decreased
antibacterial activity [125]. The N-terminal 1^18 seg-
ment had threefold lower activity against E. coli as
compared to pardaxin but had no hemolytic activity
[125]. When P7 was replaced by A in this peptide,
antibacterial activity was una¡ected though a weak
hemolytic activity was observed [126]. Introduction
of D amino acids to create diastereomers reduced
the hemolytic activity considerably whereas the anti-
bacterial activities were retained [96].
The conformations of the peptides were examined
by CD spectroscopy in aqueous TFE [95,96,125].
The helical content, as determined by a222 values,
did not directly correlate with activity. Some of the
inactive peptides did have appreciable helical con-
tent. The diastereomeric peptides did have lower hel-
ical content than pardaxin and also had lower hemo-
lytic activity. Permeabilization of model membranes
composed of PC appeared to correlate with hemo-
lytic potency. A peptide derived from the N-terminal
1^18 segment of pardaxin, GFFALIAQIISSPL-
FQTL^Am, where the K residues were replaced by
Q, had hemolytic activity but was devoid of antibac-
terial activity [126]. The peptide segment GFFALIP-
KIISSPLFK^Am, which did not have any biological
activity, could be engineered by judicious positioning
of K and P residues to generate peptides with anti-
bacterial and/or hemolytic activity [127].
In summary, studies on pardaxin and its analogs
indicate that a net cationic charge of +1 or +2 is
su⁄cient for antibacterial and hemolytic activities,
provided other features in the peptide favor pore
formation in membranes. Lower helical content spe-
ci¢cally favors speci¢c antibacterial activity as hemo-
lytic activity is considerably decreased, probably due
to ine⁄cient pore formation. The structural and
charge requirements for biological activity correlate
with model membrane permeabilization of zwitter-
ionic and anionic vesicles. It appears that in peptides
that have strong pore-forming abilities, which of
course leads to antibacterial and hemolytic activities,
modulation of structure, especially introducing struc-
tural £exibility in the molecule thereby reducing ef-
fective pore formation, results in loss of hemolytic
activity but not antibacterial activity.
4.3. Dermaseptin
Dermaseptin is a 34-residue linear peptide having
the sequence ALWKTMLKKL10 GTMALHAG-
KA20 ALGAAADTIS30 QGTQ. It has been isolated
from the skin extract of the frog Phyllomedusa sau-
vagii and is active against pathogenic fungi and bac-
teria at micromolar concentrations [128,129]. The ac-
tivities of several truncated analogs of the
antibacterial peptide have been examined. While
the analogs composed of amino acids 14^34, 16^34,
20^34, 28^34, 1^4, 1^8, 10^19 had no activity, the
peptide corresponding to residues 1^18 had activity
comparable to that of the parent peptide [130]. CD
studies indicated an K-helical conformation in TFE.
The inactive 16^34 peptide was unordered even in
TFE. The N-terminal segment of another member
of the dermaseptin family, i.e., ALWKNMLKGIG-
KLAGK^Am, also showed potent antimicrobial ac-
tivity [131]. Thus, the N-terminal segment is a major
BBAMEM 77743 25-11-99
N. Sitaram, R. Nagaraj / Biochimica et Biophysica Acta 1462 (1999) 29^54 41
determinant of structure and biological activity of
dermaseptin.
4.4. Melittin
Melittin, a 26-residue hemolytic peptide which is a
major component of the venom of European honey
bee Apis mellifera, has been the subject of extensive
investigations directed towards understanding the
molecular mechanism of hemolysis [29]. There have
been numerous studies on the interaction of melittin
with lipids with a view to understand the various
facets of the interaction of membrane proteins with
membranes [29]. The broad-spectrum antibacterial
activity of melittin was observed in 1968 [132] but
structural requirements for antibacterial activity has
been addressed only in recent years. All D-melittin
has hemolytic and antibacterial activities comparable
to the L-enantiomer, indicating the absence of chiral
recognition in the manifestation of its biological ac-
tivities [102].
The conformation of melittin (GIGAVLKVL-
TTGLPALISWIKRKRQQ^Am), as examined by
X-ray crystallography, indicates a helix^bend^helix
[133] structure with the bend region positioned be-
tween residues 11^15. Lines drawn through the helix
axes of residues 1^10 and 16^26 intersect with an
angle of V120‡. The N-terminal segment of 20-res-
idues is highly hydrophobic with only one charged
residue K at position 7. In contrast, the C-terminal 6
residue segment is highly cationic with two Ks, two
Rs, two Qs with the C-terminal also amidated. The
N-terminal helical segment is amphiphilc in nature as
shown in Fig. 4. Structure^function studies indicate
that replacement of P14 with A removes the bend in
the structure. A14 melittin was 2.5-fold more hemo-
lytic than its parent peptide, but it formed less stable
voltage-dependent channels, thereby indicating that
channel formation may not dictate its hemolytic ac-
tivity [29]. The amphiphilic helical segment of melit-
tin between residues 1^20 appears to play only a
structural role in its activity, as the actual sequence
could be replaced with a sequence capable of forming
amphiphilic K-helical structure, but having minimum
homology to the native segment, without any loss in
its activity. The segment 1^20, although membrane
active, does not possess any lytic activity. The cati-
onic segment 20^26 was also inactive [134,135].
Analysis of the antibacterial and hemolytic activ-
ities of 24 individual omission analogs of melittin
indicated that deletion of L(6), K(7), V(8), l(9),
l(13), l(16), I(17) and W(19) resulted in a consider-
able decrease in hemolytic activity [136]. However,
deletion of amino acids in the bend region did not
a¡ect hemolytic activity. The changes indicated
above also resulted in lower antibacterial activity
but the decrease in activity as compared to melittin
was less pronounced than the loss in hemolytic ac-
tivity. Interestingly, deletion of individual amino
acids in the C-terminal segment had no e¡ect on
activity. However, K7 appears to be important for
activity. Based on the analysis of retention times dur-
ing reverse-phase high-performance liquid chroma-
tography, it has been suggested that deletion of ami-
no acids that caused lower hemolytic activity had
lower amphiphilicity (decreased amphiphilicity was
correlated with early retention times). Hence, the
study clearly indicated the requirements for an am-
phiphilic structure for hemolytic activity. The anti-
microbial potencies of the various omission analogs
indicated that the requirements of amphiphilic struc-
ture for antimicrobial activity was less stringent as
compared to hemolytic activity [136].
The K at position 7 in melittin is fully solvent
exposed in the tetrameric state. The conformation
and aggregation properties, as well as biological ac-
tivities of single substitution analogs at this position,
have been examined [137]. Replacements by I, L or V
residues resulted in considerable decreases in antibac-
terial and hemolytic activities. Analogs in which the
replacements were A, D, E or G had slightly lower
hemolytic activity as compared to melittin. There
was also a decrease in antibacterial potency. All the
inactive analogs had lower hydrophobic moments as
compared to the active analogs. The active analogs
had the ability to form tetramers in the presence of
salt, unlike the inactive analogs. Analysis of CD data
by curve-¢tting methods indicated varying propor-
tions of helix and L-structures in the presence of lipid
vesicle (PC/PS). In aqueous TFE, all the peptides
had similar helical propensities. Values of the con-
centration of lipid when 50% peptide was bound did
not appear to directly correlate with biological activ-
ity. The analog in which was K7 was replaced by W
did not appear to aggregate into tetramers, but had
hemolytic activities comparable to melittin, although
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the antibacterial activity was considerably lower. CD
data also indicated the presence of helical and L-
sheet structures in the presence of lipid vesicles for
this peptide.
The requirement of amphiphilic helical structure
for hemolytic activity but not for antimicrobial ac-
tivity is also borne out by the studies on diastereo-
meric, retro and retro-enantiomers of melittin
[138,139]. Diastereomeric melittin, where V5, V8,
I17, and K21 were replaced by D-isomers, showed a
very low propensity for helical structure and did not
lyse erythrocytes but had antimicrobial activity [139].
The MIC values were only slightly higher than me-
littin. Retro melittin and retro-enantio melittin,
which had a high propensity for L-structure in aque-
ous medium but had high helical content in the pres-
ence of hexa£uoroisopropanol, had antimicrobial ac-
tivity comparable to melittin but considerably lower
hemolytic activity. Thus, hemolytic activity appears
to be sensitive to direction of amide bonds and helix
dipole moment [138].
Studies involving single amino acid omission ana-
logs of melittin revealed a critical role for W19 in its
biological activity [136]. Either chemical modi¢cation
or replacement of W19 with L resulted in a remark-
able decrease in activity, thus con¢rming the impor-
tance of this residue [140,141]. A detailed £uores-
cence study indicates that the W residue is localized
just below the head-group region in lipid bilayers
[142]. It is conceivable that this orientation is essen-
tial for activity. However, the position of W in the
sequence does not appear to be very critical for ac-
tivity, as analogs of melittin containing a single W
residue at positions 9, 11 or 17 also exhibited hemo-
lytic activities with potencies in the order MLT-
W17sMLT-W19 = MLT-W11sMLT-W9 [143].
Melittin forms tetrameric structures at high peptide
concentrations or at high salt concentrations, but the
other analogs of melittin such as MLT-W17, MLT-
W9 and MLT-W11 did not form tetramers under
these conditions. Hence, the ability to form soluble
tetrameric structures appeared to be unrelated to
lytic activity.
The segment 1^7 in melittin appears to be very
important in modulating its biophysical as well as
its biological properties, as the 8^26 peptide did
not permeabilize model lipid membranes [144]. Anti-
microbial and hemolytic activities of this fragment
are not known. A 15-residue synthetic peptide, cor-
responding to the C-terminal end of melittin, which
encompasses its most amphiphilic segment, exhibited
5^7-fold less antimicrobial activity than melittin
[145]. The hemolytic activity of this peptide was
300 times less than that of melittin. An analog of
this peptide, in which two cationic residues have
been transposed to the N-terminal region from the
C-terminal region, had antibacterial activity compar-
able to that of melittin but considerably lower he-
molytic activity. The biological activities of the pep-
tides could be rationalized on the basis of structure
and aggregation.
Hybrid peptides composed of various segments of
cecropin and melittin have been synthesized and ex-
amined for biological activity [102,146,147]. Peptides
composed of the amphiphilic 1^10 N-terminal seg-
ment of cecropin A and 1^13 region of melittin
showed broad-spectrum antimicrobial activity with
low hemolytic activity.
5. Requirements for activity in naturally occurring
short antibacterial peptides
5.1. Indolicidin
The 13-residue antibacterial peptide indolicidin,
having the primary structure ILPWKWPWWP-
WRR^Am, has a mole percentage of tryptophan
which is the highest among antibacterial peptides
[148]. The peptide has been isolated from bovine
neutrophils and belongs to the cathelicidin family
of proteins, which have a common proregion and a
variable C-terminal antimicrobial domain [149], and
is likely to have a role as a host-defense peptide. The
unusual amino acid composition has led to studies
directed towards delineation of the role of multiple
tryptophan residues in its biological activity as well
as interactions with model membranes.
5.1.1. Antimicrobial spectrum
Natural indolicidin, amidated at the C-terminal,
was found to be bactericidal against E. coli and S.
aureus in phosphate bu¡er between 10^20 Wg/ml con-
centrations and 25 Wg/ml could virtually sterilize 108
E. coli cells in V20 min [148]. Subsequently, syn-
thetic indolicidin, which was identical to natural in-
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dolicidin, was shown to exert activity against fungal
strains of Candida albicans, C. neoformins, Saccharo-
myces cerevisiae and C. utilis with comparable MICs
[150]. Synthetic analogs of indolicidin with C-termi-
nal free acid as well as C-terminal methyl ester have
also been shown to possess antimicrobial activity
against E. coli, Pseudomonas aeruginosa, Salmonella
typhimurium, S. aureus and S. epidermidis with MICs
between 4^64 Wg/ml [90]. Recently, a study compar-
ing the in vitro activity of indolicidin on 202 clinical
isolates of Gram-positive and -negative bacteria has
shown that indolicidin is e¡ective on a large number
of these isolates [151]. Indolicidin exhibits antiviral
activity against HIV-1 [152]. Although indolicidin
has impressive and potent antimicrobial activity, it
has cytotoxic activity against mammalian cells and
exhibits hemolytic activity beyond 15 WM [153]. It
also has been shown to possess cytotoxic activity
against rat and human T-lymphocytes [152].
5.1.2. Mechanism of action
Indolicidin has been shown to permeabilize the
outer membrane of E. coli [90,154]. Its C-terminal
free acid analog e¡ectively permeabilized the cyto-
plasmic membrane [90]. Experimental evidence has
not been presented for the permeabilization of the
cytoplasmic membrane for either natural indolicidin
or the C-terminal methyl ester, which closely resem-
bles the natural peptide. Based on conductance meas-
urements with planar bilayer membranes, it has been
proposed that indolicidin forms channels in lipid
membranes [90]. This suggests that membrane per-
meabilization may indeed be the basis of its antimi-
crobial action. However, treatment of microbial cells
with indolicidin does not lead to their lysis [90]. In-
dolicidin did not even render the treated cells prone
to lysis by lysozyme [90]. This is in sharp contrast to
the action of other well-characterized lytic peptides
like cecropins, magainins, defensins and SPLN,
which readily lyse the target cells [15^18]. Treatment
of E. coli cells with indolicidin induced ¢lamentation
of cells, a phenomenon observed in the case of anti-
microbial agents that block DNA synthesis [155].
Indolicidin also inhibited DNA synthesis in E. coli
at concentrations at which RNA and protein synthe-
sis were either partially a¡ected or not a¡ected at all.
Thus, inhibition of macromolecular synthesis, in ad-
dition to membrane permeabilization, appears to be
a plausible mechanism of its antimicrobial action.
Hemolytic activity, in contrast, appeared to be di-
rectly related to its membrane-associating properties,
as an analog with decreased a⁄nity for lipid vesicles
was non-hemolytic, while its antimicrobial activity
was una¡ected [156].
Hydrophobic amino acids constitute V54% of in-
dolicidin with ¢ve Ws and one each of I and L res-
idues. It also has three residues of P, an amino acid
which also is implicated in the assembly of mem-
brane proteins. Fluorescence spectroscopy and equi-
librium dialysis measurements have indicated that
indolicidin binds strongly, though reversibly, to lipid
vesicles composed of zwitterionic and anionic lipids
with free energies of transfer of 38.8 and 311.5 kcal/
mol, respectively [157]. Based on W £uorescence
data, location at the bilayer interface has been sug-
gested for indolicidin [156]. CD studies indicate that
the peptide was unordered in aqueous medium and
was more ordered in a micellar environment
[90,154,157]. It appears that the peptide does not
adopt an helical conformation. Hence, in this trypto-
phan-rich peptide, binding to model membranes as
well as antibacterial activity are observed even in the
absence of ordered secondary structure.
Several analogs have been synthesized in order to
delineate the charge requirements and also to under-
stand the importance of W and P residues for activ-
ity. Indolicidin is amidated at the C-terminal end. A
synthetic analog with C-terminal free acid (Ind-OH)
also exhibited antimicrobial activity, but an analog
with C-terminal methyl ester (Ind-OMe), which re-
sembles native peptide in its charge, was considerably
more active than Ind-OH [90]. An analog of indoli-
cidin lacking the C-terminal R13 amide of indolicidin
had much less antimicrobial and anti-fungal activity
as compared to indolicidin [152]. Introduction of K
residues in indolicidin, i.e., ILKKWPWWPWRRK
and its C-terminal methyl ester, had fourfold greater
potency than indolicidin acid but these peptides were
non-hemolytic [91]. These observations re£ect the im-
portance of a net positive charge for antibacterial
activity. Replacement of all the W residues with F
residues had no signi¢cant e¡ect on its antimicrobial
activity, but almost completely abolished its hemo-
lytic activity [154]. Tryptophan residues can promote
partitioning of the peptide into the lipid bilayer [5]
and in turn appear to play a major role in the he-
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molytic activity of indolicidin. These attributes do
not seem to be vital for its antimicrobial activity.
Other analogs of indolicidin, in which W4, W6 and
W8 were replaced by I or G residues, exhibited en-
hanced antimicrobial activity as compared to indoli-
cidin, again con¢rming the above observation [158].
However, the hemolytic activity of these analogs has
not been reported. The three P residues of indolicidin
also do not appear to be vital for its biological ac-
tivity. An analog in which all these P residues were
replaced by A had undiminished antimicrobial activ-
ity, but increased hemolytic activity [154].
5.2. Other tryptophan-rich antimicrobial peptides
A 13-residue synthetic peptide corresponding to
the tryptophan-rich region of a putative cathelicidin
obtained from the cDNA library of porcine bone
marrow had antimicrobial activity against both
Gram-positive and -negative bacteria [159]. It also
had weak activity against A. fumigatus. A family of
lipid-interacting proteins with potential antimicrobial
function, named puroindoline a and b, have recently
been characterized from wheat endosperm [160]. In-
terestingly, these proteins contain tryptophan-rich
amphiphilic domains which are important for their
physico-chemical as well as biological properties. In-
teraction of puroindoline a with model lipid mem-
branes has recently been reported and it has been
found to interact with phosphatidylglycerol vesicles
with high a⁄nity, leading to disruption of acyl chain
packing. However its interaction with phosphatidyl-
choline appears to be weak. Although the mechanism
of action is not clear, tryptophan-rich peptides do
appear to possess broad spectrum antibacterial activ-
ity.
6. Structure^function relationship studies in
antimicrobial peptides containing one or more
disul¢de bridges
6.1. Peptides containing a single disul¢de bridge
6.1.1. Ranide family of peptides
A large number of antimicrobial peptides isolated
from the Rana genus are characterized by a large
linear segment followed by a C-terminal cationic
loop linked by a disul¢de bridge containing 7 amino
acids. Examples of these peptides include brevenins
[161,162], gaegurins [163], esculentin and ranalexin
[164]. The primary structure of brevinin IE is
FLPLLAGLAANFLPKIFCKITRKC. The other
peptides which have a C-terminal loop have amino
acid compositions similar to brevenin IE but vary in
length. The C-terminal loop resembles the lipid A
binding heptapeptide ring domain of polymyxin B
and hence has been presumed to play a role in its
antimicrobial activity [162]. An analog of ranalexin
in which the C-terminal cysteine was deleted exhib-
ited a 32-fold decrease in antimicrobial activity, in
agreement with the above assumption [164]. How-
ever, reduction of disul¢de bridges in ranalexin and
replacement of cysteines did not markedly decrease
the activity, suggesting that the disul¢de bridge in
ranalexin did not play a major role in its activity
[165]. The decrease in activity due to deletion of
the C-terminal cysteine appears to re£ect a crucial
role for this residue for its activity rather than a
requirement for a disul¢de bond. Similar results
have been obtained in the case of brevenin 1E and
gaegurin, which have two cysteine residues linked by
a disul¢de bridge [166^168].
6.1.2. Bactenecin
Bactenecin, a dodecapeptide from bovine neutro-
phils, having the sequence RLCRIVVIRVCR exhib-
its potent antibacterial activity [169]. The CD spec-
trum of the peptide in phosphate bu¡er is typical of
peptides with type I L-turn, with a characteristic neg-
ative ellipticity at 205 nm [92]. The same structure
was also observed in TFE, SDS and liposomes com-
posed of anionic lipids. Computer modeling studies,
correlated with the structure indicated by the CD
spectra, suggest that the peptide adopts a rigid L-
turn loop structure irrespective of its environment.
Structure^activity studies on bactenecin have re-
vealed some interesting aspects of its activity. The
naturally occurring cyclic peptide possessed activity
primarily against Gram-negative bacteria with activ-
ity against a few strains of Gram-positive bacteria
[92]. The linearized peptide obtained by reduction
of the disul¢de bridge or replacement of C with S
exhibited activity against Gram-positive bacteria
with virtually no activity against Gram-negative bac-
teria except for strains with altered OM. The cyclic
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and linear analogs were capable of permeabilizing
the outer membrane of Gram-negative bacteria,
with the cyclic form more e¡ective than the linear-
ized peptide. However, only the linear analog e¡ec-
tively permeabilized the cytoplasmic membrane. The
linear analogs assumed predominantly K-helical
structure in TFE but L-sheet structure in the pres-
ence of liposomes or detergent. Increasing the num-
ber of positive charges at the N- and C-termini and
adding an extra W residue increased the activity of
bactenecin analogs against Gram-positive and -neg-
ative bacteria and also broadened the antimicrobial
spectrum [170].
6.2. Peptides with two disul¢de bridges
Antimicrobial peptides containing four cysteine
residues linked by two disul¢de bonds with bicyclic
structures have been characterized from the hemo-
lymph of the horseshoe crabs Tachypleus tridentatus
and Limulus polyphemus [171^173] as well as from
porcine leukocytes [174^176]. These are known as
tachyplesins (KWCFRVCYRGICYRRCR-Am, ta-
chyplesin-1), polyphemusins (RRWCFRVCYRGF-
CYRKCR-Am, polyphemusin-1), and protegrins
(RGGRLCYCRRRFCVCVGR-Am, PG-1), respec-
tively. These peptides are between 16 and 18 residues
in length and adopt an antiparallel L-sheet structure
which is stabilized by the two disul¢de bridges. All
these peptides exhibit broad spectrum antimicrobial
activity and appear to function by membrane disrup-
tion. They also possess antiviral activity against
HIV-1. Studies aimed at understanding the impor-
tance of the disul¢de bridges for their activity have
been carried out on this group of peptides. Studies
with tachyplesin analogs, where the SH groups were
chemically protected to prevent cyclization or cys-
teines were replaced by A residues, suggested that
the cyclic structure was essential for antimicrobial
activity while it might not be crucial for membrane
permeabilization [177^180]. Detailed studies have in-
dicated that replacement of the cysteine residues by
certain amino acid like A, D and I lead to inactiva-
tion, whereas analogs with aromatic residues F and
Y and hydrophobic amino acid like L, M and V
retained broad spectrum antimicrobial activity
[181]. These results suggest subtle in£uences of the
amino acid side chains on the overall conformation
of the analog [179].
Tamamura et al. have attempted to develop less
toxic analogs of polyphemusin with improved ac-
tivity against HIV [181,182]. An analog of polyphe-
musin II having the replacements [(Y5,12, K7)] was
found to be considerably less cytotoxic but retained
the antiviral potency of its parent peptide. An analog
with only one S^S bridge, RRWCYRKDKPYRK-
CR^Am, had antiviral activities comparable to the
parent peptide polyphemusin II but was less cyto-
toxic.
Protegrin adopts L-sheet a structure in aqueous
and membrane-mimetic environments whereas the
linear variants were unordered in water and helical
in membrane-mimetic environments [183]. Hence, the
intramolecular disul¢de bonds appear to be essential
for L-sheet formation and potent antibacterial activ-
ity in media comparable to those found in serum and
extracellular £uids. Protegrin and its linear variants
were active in the absence of high salt at comparable
concentrations, but the S^S bridges were necessary
for activity at high salt concentrations and for pore
formation [184].
Structure^function studies on mammalian defen-
sins involving truncated analogs have not been ex-
tensive. The L-hairpin region of rabbit defensin NP-2
(composed of 18 amino acids) has been shown to
have antibacterial activity [185].
7. Mechanisms of model membrane permeabilization
It is clearly evident that positive charges play an
important role in determining antibacterial activity
whereas an amphiphilic helical structure is necessary
for hemolytic activity. Considerable information
about the orientation of peptides on the membrane
surface and the possible structure of the pores has
emerged from detailed studies on magainin and to a
lesser extent on cecropins and defensins. Some recent
¢ndings are reviewed in this section. The ability of
magainins to permeabilize lipid vesicles was ¢rst
studied by Matsuzaki et al. by monitoring the release
of entrapped calcein from small unilamellar vesicles
[186]. It was observed that PS but not PC vesicles
were permeabilized by the peptide. By analyzing both
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the peptide and lipid concentration dependence of
the leakage rate, the a⁄nity of peptide for lipid
vesicles and the amount of membrane-bound peptide
were evaluated. A binding constant of 105M31 was
observed for PS vesicles. The data did not suggest
extensive aggregation of peptide in membranes
although 100^300 molecules were apparently bound
to one vesicle. While the peptide was unordered in
aqueous medium and PC vesicles, a helical confor-
mation was observed in the presence of PS vesicles.
The lipid/peptide ratio at which substantial calcein
was released was V10:1, indicating that the peptide
did not permeabilize even PS vesicles e¡ectively, un-
like the cytolytic peptides, melittin and pardaxin.
Magainin^lipid interactions have been extensively in-
vestigated [187^201]. Judiciously designed analogs
and studies involving CD spectroscopy and calcein
release have clari¢ed magainin^lipid interactions to a
considerable extent. Studies using systematic double
D-amino acid replacement have revealed that upon
binding to liposomes, a stable K-helix appears to be
formed between residues 9 and 21 with the N-termi-
nal 1^8 segment forming a £exible K-helix. Binding
to negatively charged vesicles was independent of the
content of negative charges and a well-stabilized he-
lix between residues 9^21 was important for this in-
teraction [190]. The charges in the polar face in mag-
ainin appear to be optimized for interaction with
negatively charged vesicles, as analogs where the an-
gle subtended by the positively charged helix face, as
well as those with greater hydrophobic moment than
in magainin, were able to permeabilize PC vesicles
but could permeabilize PG vesicles less e¡ectively
[194,195,197]. The question of magainin aggregation
on the membrane surface in the bilayer and the
structure of the pore has been the subject of exten-
sive studies. One and two dimensional solid state
15N-NMR data of speci¢cally labeled 15N magainin
2 in oriented bilayer samples have been interpreted as
the peptide oriented parallel to the membrane sur-
face. An orientation parallel to the bilayer surface at
low peptide lipid molar ratios and perpendicular ori-
entation at a high lipid/peptide ratio has been sug-
gested based on oriented CD data [200]. Fluores-
cence energy transfer experiments involving W16
magainin and NK dansyl £uorophore [196] appear
to suggest an orientation parallel to the membrane
surface and absence of association of magainin mol-
ecules on the membrane surface. However, a model
for the magainin pore proposed by Matsuzaki and
co-workers involves oligomerization of peptides with
4^5 molecules involved in forming a pore [188,189].
The aggregation number of 5 has been arrived at by
analysis of the calcein release pro¢les as a function of
peptide concentration and accounting for transloca-
tion of peptide molecules to the inner lea£et. Studies
on planar bilayers have indicated an aggregation
number in the range of 3^6 [74]. The variation in
the number of molecules in the aggregates suggests
that well-de¢ned aggregates are perhaps not formed
and the experimentally determined values are aver-
ages. The model proposed for membrane permeabi-
lization by magainin involves binding of magainin
molecules on the membrane surface followed by for-
mation of a pore composed of peptide^lipid com-
plexes, which on disintegration leads to translocation
of magainin molecules to the inner lea£et [189,191^
193]. The model involving lipid head groups as part
of the channel has also been proposed by Ludtke et
al. [201]. It is evident that this model, referred to as
toroidal model, proposed for the magainin pore is
considerably di¡erent from those of gramicidin A
and alamethicin. The rapid £ip-£op of phospholipids
induced by magainin [191] is presumed to arise due
to the formation of toroidal pores.
The question of the speci¢city of magainin for
prokaryotic membranes has been addressed. The in-
ability of magainin to bind to zwitterionic vesicles
has been suggested as a reason for its lack of hemo-
lytic activity as erythrocytes do not have negatively
charged lipids on the outer monolayer. Magainin can
cause lysis when a negative inside potential is gener-
ated. Hence, lysis of erythrocytes does not occur due
to lack of membrane potential [202]. Another view-
point that has been presented is that peptide^choles-
terol interaction in the membrane inhibit the forma-
tion of structures capable of lysis. The speci¢c
activity against tumorigenic cells could arise as there
is 3^8-fold more of the negatively charged lipid, PS,
on the cell surface of transformed cells as compared
to normal cells, and magainins could bind to these
molecules and cause the permeabilization of the plas-
ma membrane [203].
Magainin 2 and a related frog skin peptide PGLa
(see Table 1 for sequence) have been shown to ex-
hibit synergism in their activities [204,205]. The syn-
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ergism is presumed to arise as a result of the forma-
tion of heterosupra molecular complexes which form
pores at a faster rate as compared to magainins and
which are also moderately more stable than the mag-
ainin pores.
The binding of the 34-residue frog skin peptide
dermaseptin with model membranes has been inves-
tigated by monitoring the £uorescence of the extrin-
sic £uorophores 7-nitrobenz-2-oxa-1,3-diazole-4-yl
(NBD), £uorescein or rhodamine-labeled peptides
in the presence of lipid vesicles of varying composi-
tion [206]. The surface partition coe⁄cients derived
from the binding isotherms indicated that the peptide
associated with negatively charged vesicles like PG to
a fourfold greater extent than zwitterionic vesicles.
The peptide also permeabilized PG containing
vesicles more e¡ectively than PC vesicles. It has
been proposed that the dermaseptin molecules bind
to the anionic membrane surface from an initial ran-
dom conformation and binding induces a helical con-
formation which is amphiphilic. This conformation
has been proposed to generate a dipole moment
along the helix axis equivalent to a half-negative
charge on the C-terminus and a half-positive charge
on the N-terminus. The opposed electric ¢elds be-
tween this dipole and the di¡erence of potential
across the plasma membrane results in the insertion
of the peptide chain into the lipid bilayer in a trans-
verse orientation which would perturb the bilayer
structure. Aggregation of several monomers would
result in additional perturbation resulting in perme-
abilization by pore formation. The N-terminal seg-
ment is presumed to be associated with the bilayer
[130].
The interaction of mammalian cecropin P1 to
model membranes has been studied by ATR-FTIR
spectroscopy and molecular dynamics simulations
[72] and £uorescence spectroscopy [207]. The data
have been interpreted in terms of a parallel orienta-
tion at the membrane surface. Since the acyl chains
were not perturbed, it appears that the peptide does
not penetrate the hydrophobic core. The peptide was
found to associate with zwitterionic as well as neg-
atively charged vesicles. The model for cecropin P1-
induced membrane permeabilization involves desta-
bilization of the phospholipid packing leading to dis-
integration as a result of the formation of a layer of
peptide monomers on the membrane surface.
Cecropin A has been shown to dissipate membrane
potential at low concentrations and cause the release
of calcein from lipid vesicles composed of both zwit-
terionic and cationic lipids. At low concentrations
when depolarization of vesicle membrane occurs,
no release of calcein was observed. Although cecro-
pin A binds more strongly to anionic lipids, this does
not result in greater membrane permeabilization of
lipid vesicles as compared to membranes with zwit-
terionic lipids. The peptide could permeabilize
vesicles containing cholesterol [208]. Cecropin B2, a
variant of cecropin A, also bound to negatively
charged vesicles more e¡ectively, but unlike cecropin
A, permeabilized them to a greater extent than zwit-
terionic vesicles [35]. Cecropin B2, like cecropin A, is
also presumed to bind to phospholipids as monomers
and orient parallel to the membrane surface. The
binding of cecropin B to lipid vesicles was recently
investigated by surface plasmon resonance and stop
£ow measurement of CD and £uorescence [36].
These studies indicated that stronger binding did
not result in increased membrane permeabilization.
Helix formation appeared to be a one-step process
whereas vesicle lysis was a two-step process. A pep-
tide composed of the N-terminal regions 1^8 of ce-
cropin A and 1^18 of melittin showed preferential
activity towards PS vesicles. A high peptide stoichi-
ometry was required for vesicle disruption as for
magainin and cecropins [209].
Defensins, which have three S^S bridges, have also
been shown to form weakly anion-selective voltage-
dependent channels independent of lipid composition
[77]. Measurement of the dependence of the loga-
rithm of membrane conductance on the logarithm
of defensin NP-1 concentration indicated an aggre-
gation number of 2^4. The defensins carry a net pos-
itive charge between +2 to +9, suggesting that their
membrane activity would be highly variable. An in-
vestigation on human defensins HNP-1 and HNP-2
(net charge = +3) indicated binding to PG vesicles
but not to PC vesicles [210,211]. The PG vesicles
aggregated in the presence of HNP-2. However, no
release of vesicular contents was detected although
lipid mixing was detected. This was attributed to
hemifusion. Based on the analysis of the release of
trapped markers, it has been proposed that HNP-2
forms multimeric pores in lipid bilayers composed of
6^8 bilayer-spanning defensin dimers in the form of
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an annulus around an aqueous channel of V25A
diameter. HNP-1 could also induce fusion of PG-
containing vesicles [210]. Rabbit defensins also have
the ability to bind to lipid vesicles composed of
POPG or POPG with neutral phospholipids and
but could cause fusion of only POPG phospholipid
vesicles [212]. While rabbit defensin NP-4 did not
cause leakage of vesicle contents, the other defensins
(NP-1, NP-2, NP-3A, NP-3B and NP-5) caused re-
lease of vesicle contents in a graded manner, as
against the ‘all or none’ mechanism of HNP-2. In
another study, Histova et al. have shown that per-
meabilization of large unilamellar vesicles made from
E. coli lipid extracts by rabbit defensins was consid-
erably di¡erent from that of composed of pure phos-
pholipids [213]. Cardiolipin appeared to play a key
role as no leakage was observed when only PG and
PE were present. Maximal release was observed at a
lipid/peptide molar ratio of V40:1 with the E. coli
lipids. The release with synthetic lipids occurred only
at a much lower lipid/peptide ratio. Based on their
data, the authors have concluded that rabbit defen-
sins do not form pores like human defensin. Di¡er-
ential scanning microcalorimetry studies have indi-
cated that the defensin HNP-2 a¡ected the phase
behavior of molecular membranes composed of lip-
ids mimicking bacterial lipids but not erythrocyte
lipids [214]. Insect defensin A, which has helical
and L-sheet segments, was also shown to interact
preferentially with anionic lipids [215].
Tachyplesin 1, like defensin, also showed speci¢c
interaction with PG vesicles causing the release of
entrapped calcein [178]. Maximal release was ob-
served at lipid/peptide ratio of V50:1. The molecule
was located below the head-group region. Although
tachyplesin 1 is not amphiphilic in aqueous environ-
ment, it has been proposed that interaction with lipid
vesicles induces amphiphilic structure. Tachyplesin 1
without the S^S bridge also associated with lipid
vesicles causing fusion/aggregation. However, mem-
brane permeabilization was attributed to disruption
of lipid organization rather than pore formation.
8. Conclusions and perspectives
Extensive studies on endogenous host-defense pep-
tides, as well as on peptides derived from them, in-
dicate that the presence of positive charges is perhaps
the most important determinant for activity. How-
ever, the number of positive charges required for
activity is variable. Although linear antibacterial pep-
tides do tend to form amphiphilic helical structures
in hydrophobic environments, antibacterial activity
has been observed even when only a small fraction
of molecules populate the helical conformation. In
fact, when peptides possessing both antibacterial
and hemolytic activities were engineered so as to de-
crease helical propensity, the antibacterial activity or
spectrum were largely una¡ected whereas there was
considerable loss in hemolytic activity. The common
structural feature in antibacterial peptides containing
two and three disul¢de bridges is a L-sheet structure.
However, in the two disul¢de bridge-containing pep-
tides, antibacterial activity is observed in the linear-
ized peptides, though to a lower extent as compared
to the parent peptide. Hence, it is evident that re-
quirements of charge and amphiphilic helical struc-
ture or L-structure for antimicrobial activity are not
stringent.
Killing of bacteria by membrane permeabilization
appears to be the mechanism of action of the anti-
bacterial peptides described in this review. The kill-
ing of bacteria appears to be rapid and multiple
mechanisms of action, especially involving perturba-
tion of cellular metabolism, are yet to be established
unequivocally. Although antimicrobial peptides do
permeabilize lipid vesicles, the lipid/peptide ratios
for e¡ective permeabilization are low, suggesting
that membrane permeabilization probably does not
occur as a result of pores formed by aggregates of
peptides. A model for the manner in which the bac-
terial membranes are permeabilized is shown in Fig.
5. The membrane surface of bacteria composed of
LPS or peptidoglycans are destabilized, resulting in
generation of a pathway for peptides to enter the
cells and bind to the bacterial plasma membrane.
Binding of the cationic peptides to the negatively
charged membrane surface results in membrane de-
stabilization which could cause defects through
which the bacterial membrane potential could be dis-
sipated. It is also likely that some peptides like the
magainins form toroidal pores composed of lipid
molecules associated with peptides.
The bacterial plasma membrane contains enzymes
necessary for respiration. Even slight damage to the
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membrane can result in loss of respiratory function.
However, lysis of erythrocytes involves creation of
pores through which ions are able to leak. When
the capacity of the Na pump to prevent excessive
entry of Na, Cl3 and water is exceeded, colloid
osmotic lysis occurs [216]. Hence, peptides that can
e¡ectively form pores exhibit both antibacterial and
hemolytic activities. Peptides that do not form pores
e¡ectively, as a result of which the Na pump can
overcome osmotic imbalance, exhibit selective anti-
bacterial activity as the bacterial membranes would
be much more susceptible to membrane damage.
It is thus evident that the mechanism of action of
antibacterial peptides that act by permeabilizing
membranes can to a large extent be rationalized on
the basis of biophysical principles.
There have been recent reports of resistance to
cationic antibacterial peptides in Salmonella, E. coli
and Y. enterocolitica, and S. aureus [99,100,217^219].
Resistance in Salmonella appears to stem from in-
creased acylation of lipid A, the major component
of the outer lea£et of the outer membrane [99]. The
resistance of B. bronchiseptica to cationic antimicro-
bial peptides is presumed to arise due to the structure
of lipopolysaccharide, which prevents e¡ective mem-
brane permeabilization [100]. In S. aureus, lower sen-
sitivity to cationic antibacterial peptides appears to
arise as a result of altered structure of teichoic acids,
a major component of the Gram-positive cell wall
[219]. Hence, the design of e¡ective membrane-active
antimicrobial peptides will be a continuous chal-
lenge.
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